dexmedetomidine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 835 | 113775-47-6 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A imidazole derivative that is an agonist of ADRENERGIC ALPHA-2 RECEPTORS. It is closely-related to MEDETOMIDINE, which is the racemic form of this compound.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 1 | mg | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.09 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| Vd (Volume of distribution) | 1.60 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 11 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.06 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 2.20 hours | Lombardo F, Berellini G, Obach RS |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Dec. 17, 1999 | FDA | HOSPIRA | |
| Jan. 29, 2001 | PMDA | Abbott Japan, Maruishi Pharmaceutical |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Bradycardia | 186.95 | 34.75 | 89 | 3253 | 64337 | 50537445 |
| Product administered to patient of inappropriate age | 99.50 | 34.75 | 25 | 3317 | 2605 | 50599177 |
| Upper airway obstruction | 80.83 | 34.75 | 16 | 3326 | 557 | 50601225 |
| Delirium | 78.88 | 34.75 | 42 | 3300 | 38150 | 50563632 |
| Floppy iris syndrome | 75.90 | 34.75 | 12 | 3330 | 108 | 50601674 |
| Hypotension | 73.94 | 34.75 | 84 | 3258 | 235385 | 50366397 |
| Agitation | 70.84 | 34.75 | 44 | 3298 | 53340 | 50548442 |
| Glossoptosis | 66.96 | 34.75 | 10 | 3332 | 59 | 50601723 |
| Respiratory acidosis | 66.74 | 34.75 | 22 | 3320 | 6006 | 50595776 |
| Respiratory depression | 65.62 | 34.75 | 26 | 3316 | 11984 | 50589798 |
| Sinus arrest | 63.52 | 34.75 | 16 | 3326 | 1682 | 50600100 |
| Cardiac arrest | 61.57 | 34.75 | 48 | 3294 | 83603 | 50518179 |
| Laryngeal stenosis | 58.70 | 34.75 | 13 | 3329 | 784 | 50600998 |
| Generalised tonic-clonic seizure | 54.48 | 34.75 | 29 | 3313 | 26281 | 50575501 |
| Tachyphylaxis | 53.55 | 34.75 | 10 | 3332 | 254 | 50601528 |
| Hepatic function abnormal | 51.23 | 34.75 | 30 | 3312 | 32651 | 50569131 |
| Withdrawal syndrome | 49.92 | 34.75 | 24 | 3318 | 17566 | 50584216 |
| Local anaesthetic systemic toxicity | 45.17 | 34.75 | 10 | 3332 | 602 | 50601180 |
| Product closure removal difficult | 44.24 | 34.75 | 6 | 3336 | 15 | 50601767 |
| Respiratory failure | 43.85 | 34.75 | 41 | 3301 | 91140 | 50510642 |
| Ventricular dysfunction | 43.34 | 34.75 | 13 | 3329 | 2608 | 50599174 |
| Acute respiratory distress syndrome | 42.95 | 34.75 | 23 | 3319 | 21076 | 50580706 |
| Abdominal compartment syndrome | 40.73 | 34.75 | 9 | 3333 | 537 | 50601245 |
| Hyperthermia | 39.73 | 34.75 | 16 | 3326 | 7680 | 50594102 |
| Aplastic anaemia | 39.72 | 34.75 | 16 | 3326 | 7687 | 50594095 |
| Laryngospasm | 38.76 | 34.75 | 12 | 3330 | 2676 | 50599106 |
| Drug interaction | 37.01 | 34.75 | 55 | 3287 | 199566 | 50402216 |
| Device pacing issue | 36.30 | 34.75 | 6 | 3336 | 73 | 50601709 |
| Myoclonus | 35.84 | 34.75 | 18 | 3324 | 14452 | 50587330 |
| Hypernatraemia | 35.62 | 34.75 | 14 | 3328 | 6307 | 50595475 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Bradycardia | 232.30 | 24.34 | 142 | 4878 | 65487 | 29504020 |
| Cardiac arrest | 157.61 | 24.34 | 124 | 4896 | 85467 | 29484040 |
| Hyperthermia | 144.97 | 24.34 | 56 | 4964 | 9374 | 29560133 |
| Diabetes insipidus | 134.37 | 24.34 | 38 | 4982 | 2396 | 29567111 |
| Product administered to patient of inappropriate age | 88.15 | 24.34 | 28 | 4992 | 2627 | 29566880 |
| Delirium | 87.57 | 24.34 | 64 | 4956 | 39333 | 29530174 |
| Arteriospasm coronary | 84.95 | 24.34 | 27 | 4993 | 2538 | 29566969 |
| Seizure like phenomena | 79.68 | 24.34 | 19 | 5001 | 607 | 29568900 |
| Postoperative ileus | 74.12 | 24.34 | 18 | 5002 | 622 | 29568885 |
| Hyperthermia malignant | 72.63 | 24.34 | 22 | 4998 | 1762 | 29567745 |
| Intestinal pseudo-obstruction | 70.58 | 24.34 | 20 | 5000 | 1268 | 29568239 |
| Drug withdrawal syndrome | 68.70 | 24.34 | 41 | 4979 | 17943 | 29551564 |
| Hypotension | 66.11 | 24.34 | 118 | 4902 | 194236 | 29375271 |
| Acute motor axonal neuropathy | 58.75 | 24.34 | 10 | 5010 | 51 | 29569456 |
| Electrocardiogram QT prolonged | 55.01 | 24.34 | 47 | 4973 | 36090 | 29533417 |
| Burkholderia test positive | 52.43 | 24.34 | 15 | 5005 | 984 | 29568523 |
| Myoclonus | 49.92 | 24.34 | 30 | 4990 | 13279 | 29556228 |
| Respiratory failure | 49.45 | 24.34 | 71 | 4949 | 97060 | 29472447 |
| Epidermolysis bullosa | 46.08 | 24.34 | 9 | 5011 | 108 | 29569399 |
| Off label use | 45.10 | 24.34 | 132 | 4888 | 300668 | 29268839 |
| Upper airway obstruction | 45.03 | 24.34 | 12 | 5008 | 604 | 29568903 |
| Polyuria | 42.39 | 24.34 | 22 | 4998 | 7340 | 29562167 |
| Malignant catatonia | 39.97 | 24.34 | 9 | 5011 | 222 | 29569285 |
| Serotonin syndrome | 37.83 | 24.34 | 28 | 4992 | 17484 | 29552023 |
| Laryngomalacia | 37.25 | 24.34 | 9 | 5011 | 304 | 29569203 |
| Tachypnoea | 34.53 | 24.34 | 25 | 4995 | 15090 | 29554417 |
| Agitation | 34.49 | 24.34 | 43 | 4977 | 51261 | 29518246 |
| Fatigue | 32.72 | 24.34 | 7 | 5013 | 316814 | 29252693 |
| Tachycardia | 32.59 | 24.34 | 50 | 4970 | 72360 | 29497147 |
| Floppy iris syndrome | 32.33 | 24.34 | 8 | 5012 | 299 | 29569208 |
| Hypernatraemia | 31.24 | 24.34 | 18 | 5002 | 7368 | 29562139 |
| Macule | 30.78 | 24.34 | 10 | 5010 | 1006 | 29568501 |
| Urinary bladder rupture | 29.86 | 24.34 | 6 | 5014 | 84 | 29569423 |
| Product use issue | 29.71 | 24.34 | 40 | 4980 | 51404 | 29518103 |
| Cardiac arrest neonatal | 29.13 | 24.34 | 5 | 5015 | 27 | 29569480 |
| Ventricular fibrillation | 29.11 | 24.34 | 23 | 4997 | 15810 | 29553697 |
| Neuroleptic malignant syndrome | 28.71 | 24.34 | 23 | 4997 | 16125 | 29553382 |
| Sedation complication | 28.50 | 24.34 | 10 | 5010 | 1272 | 29568235 |
| Abdominal compartment syndrome | 28.47 | 24.34 | 9 | 5011 | 830 | 29568677 |
| Drug withdrawal syndrome neonatal | 28.10 | 24.34 | 13 | 5007 | 3382 | 29566125 |
| Glossoptosis | 27.57 | 24.34 | 6 | 5014 | 126 | 29569381 |
| Torsade de pointes | 27.55 | 24.34 | 16 | 5004 | 6645 | 29562862 |
| Sinus arrest | 27.32 | 24.34 | 10 | 5010 | 1437 | 29568070 |
| Transcranial electrical motor evoked potential monitoring abnormal | 25.18 | 24.34 | 4 | 5016 | 12 | 29569495 |
| Multiple organ dysfunction syndrome | 24.83 | 24.34 | 41 | 4979 | 63075 | 29506432 |
| Methaemoglobinaemia | 24.54 | 24.34 | 11 | 5009 | 2660 | 29566847 |
| Postresuscitation encephalopathy | 24.50 | 24.34 | 4 | 5016 | 15 | 29569492 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Bradycardia | 348.82 | 25.17 | 203 | 7736 | 118016 | 64372777 |
| Cardiac arrest | 201.45 | 25.17 | 160 | 7779 | 153904 | 64336889 |
| Hyperthermia | 180.56 | 25.17 | 69 | 7870 | 15481 | 64475312 |
| Diabetes insipidus | 140.26 | 25.17 | 42 | 7897 | 4479 | 64486314 |
| Product administered to patient of inappropriate age | 139.54 | 25.17 | 42 | 7897 | 4559 | 64486234 |
| Delirium | 124.08 | 25.17 | 87 | 7852 | 69107 | 64421686 |
| Postoperative ileus | 108.48 | 25.17 | 25 | 7914 | 956 | 64489837 |
| Upper airway obstruction | 107.41 | 25.17 | 26 | 7913 | 1232 | 64489561 |
| Hypotension | 103.40 | 25.17 | 175 | 7764 | 380799 | 64109994 |
| Respiratory depression | 92.79 | 25.17 | 49 | 7890 | 23394 | 64467399 |
| Agitation | 90.81 | 25.17 | 80 | 7859 | 88287 | 64402506 |
| Myoclonus | 84.12 | 25.17 | 47 | 7892 | 25071 | 64465722 |
| Drug withdrawal syndrome | 79.60 | 25.17 | 49 | 7890 | 31242 | 64459551 |
| Polyuria | 75.59 | 25.17 | 35 | 7904 | 12608 | 64478185 |
| Respiratory failure | 75.57 | 25.17 | 96 | 7843 | 161087 | 64329706 |
| Glossoptosis | 75.27 | 25.17 | 14 | 7925 | 180 | 64490613 |
| Hyperthermia malignant | 72.63 | 25.17 | 22 | 7917 | 2437 | 64488356 |
| Generalised tonic-clonic seizure | 71.11 | 25.17 | 50 | 7889 | 39807 | 64450986 |
| Intestinal pseudo-obstruction | 68.22 | 25.17 | 20 | 7919 | 1980 | 64488813 |
| Electrocardiogram QT prolonged | 68.09 | 25.17 | 65 | 7874 | 79383 | 64411410 |
| Sinus arrest | 67.68 | 25.17 | 22 | 7917 | 3068 | 64487725 |
| Seizure like phenomena | 67.44 | 25.17 | 19 | 7920 | 1633 | 64489160 |
| Off label use | 65.54 | 25.17 | 198 | 7741 | 632608 | 63858185 |
| Abdominal compartment syndrome | 65.52 | 25.17 | 18 | 7921 | 1410 | 64489383 |
| Serotonin syndrome | 64.84 | 25.17 | 47 | 7892 | 39235 | 64451558 |
| Hypernatraemia | 64.43 | 25.17 | 31 | 7908 | 12158 | 64478635 |
| Tachypnoea | 63.51 | 25.17 | 40 | 7899 | 26531 | 64464262 |
| Respiratory acidosis | 58.03 | 25.17 | 27 | 7912 | 9828 | 64480965 |
| Acute motor axonal neuropathy | 56.34 | 25.17 | 10 | 7929 | 97 | 64490696 |
| Withdrawal syndrome | 55.23 | 25.17 | 35 | 7904 | 23457 | 64467336 |
| Drug interaction | 53.12 | 25.17 | 129 | 7810 | 361954 | 64128839 |
| Laryngeal stenosis | 50.48 | 25.17 | 13 | 7926 | 794 | 64489999 |
| Tachycardia | 48.95 | 25.17 | 75 | 7864 | 149504 | 64341289 |
| Atrioventricular block second degree | 48.59 | 25.17 | 21 | 7918 | 6433 | 64484360 |
| Arteriospasm coronary | 48.54 | 25.17 | 20 | 7919 | 5445 | 64485348 |
| Epidermolysis bullosa | 43.29 | 25.17 | 9 | 7930 | 211 | 64490582 |
| Arthralgia | 42.91 | 25.17 | 3 | 7936 | 442257 | 64048536 |
| Delayed recovery from anaesthesia | 42.26 | 25.17 | 13 | 7926 | 1515 | 64489278 |
| Multiple organ dysfunction syndrome | 42.17 | 25.17 | 57 | 7882 | 101356 | 64389437 |
| Fatigue | 41.93 | 25.17 | 20 | 7919 | 748710 | 63742083 |
| Product closure removal difficult | 40.02 | 25.17 | 5 | 7934 | 0 | 64490793 |
| Laryngospasm | 38.93 | 25.17 | 15 | 7924 | 3430 | 64487363 |
| Hypoxia | 38.88 | 25.17 | 51 | 7888 | 88098 | 64402695 |
| Torsade de pointes | 38.66 | 25.17 | 25 | 7914 | 17338 | 64473455 |
| Malignant catatonia | 38.46 | 25.17 | 9 | 7930 | 368 | 64490425 |
| Ventricular fibrillation | 38.11 | 25.17 | 28 | 7911 | 23832 | 64466961 |
| Local anaesthetic systemic toxicity | 37.85 | 25.17 | 10 | 7929 | 675 | 64490118 |
| Hepatic function abnormal | 37.76 | 25.17 | 43 | 7896 | 64270 | 64426523 |
| Ventricular tachycardia | 37.11 | 25.17 | 32 | 7907 | 34233 | 64456560 |
| Neuroleptic malignant syndrome | 36.95 | 25.17 | 28 | 7911 | 24968 | 64465825 |
| Drug reaction with eosinophilia and systemic symptoms | 36.59 | 25.17 | 39 | 7900 | 54178 | 64436615 |
| Sedation complication | 36.36 | 25.17 | 20 | 7919 | 10334 | 64480459 |
| Burkholderia test positive | 34.62 | 25.17 | 9 | 7930 | 570 | 64490223 |
| Nausea | 34.31 | 25.17 | 28 | 7911 | 785772 | 63705021 |
| Blood pressure decreased | 33.65 | 25.17 | 47 | 7892 | 86152 | 64404641 |
| Acute respiratory distress syndrome | 33.60 | 25.17 | 32 | 7907 | 38903 | 64451890 |
| Transcranial electrical motor evoked potential monitoring abnormal | 32.84 | 25.17 | 5 | 7934 | 16 | 64490777 |
| Product use in unapproved indication | 32.57 | 25.17 | 69 | 7870 | 176549 | 64314244 |
| Airway complication of anaesthesia | 32.54 | 25.17 | 8 | 7931 | 404 | 64490389 |
| Malaise | 32.51 | 25.17 | 5 | 7934 | 396242 | 64094551 |
| Device pacing issue | 31.65 | 25.17 | 6 | 7933 | 86 | 64490707 |
| Oxygen saturation decreased | 31.25 | 25.17 | 51 | 7888 | 107125 | 64383668 |
| Sinus bradycardia | 30.26 | 25.17 | 24 | 7915 | 22869 | 64467924 |
| Anaphylactic shock | 30.19 | 25.17 | 27 | 7912 | 30301 | 64460492 |
| Diarrhoea | 30.01 | 25.17 | 27 | 7912 | 722677 | 63768116 |
| Headache | 28.30 | 25.17 | 15 | 7924 | 529452 | 63961341 |
| Dizziness | 28.12 | 25.17 | 9 | 7930 | 430154 | 64060639 |
| Asthenia | 27.90 | 25.17 | 9 | 7930 | 428035 | 64062758 |
| Stress cardiomyopathy | 27.43 | 25.17 | 16 | 7923 | 9241 | 64481552 |
| Pain in extremity | 26.82 | 25.17 | 3 | 7936 | 303082 | 64187711 |
| Ventricular dysfunction | 26.63 | 25.17 | 13 | 7926 | 5257 | 64485536 |
| Aplastic anaemia | 26.06 | 25.17 | 18 | 7921 | 13902 | 64476891 |
| Drug ineffective for unapproved indication | 25.75 | 25.17 | 25 | 7914 | 31108 | 64459685 |
| Atrioventricular block complete | 25.49 | 25.17 | 18 | 7921 | 14400 | 64476393 |
| Macule | 25.42 | 25.17 | 10 | 7929 | 2416 | 64488377 |
| Product use issue | 25.37 | 25.17 | 57 | 7882 | 151658 | 64339135 |
| Septic shock | 25.26 | 25.17 | 46 | 7893 | 105391 | 64385402 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | N05CM18 | NERVOUS SYSTEM PSYCHOLEPTICS HYPNOTICS AND SEDATIVES Other hypnotics and sedatives |
| FDA MoA | N0000009918 | Adrenergic alpha2-Agonists |
| FDA EPC | N0000175554 | Central alpha-2 Adrenergic Agonist |
| CHEBI has role | CHEBI:35569 | alpha-adrenergic agonists |
| CHEBI has role | CHEBI:35717 | hypnotics |
| FDA PE | N0000175975 | General Anesthesia |
| MeSH PA | D018663 | Adrenergic Agents |
| MeSH PA | D000322 | Adrenergic Agonists |
| MeSH PA | D058647 | Adrenergic alpha-2 Receptor Agonists |
| MeSH PA | D000316 | Adrenergic alpha-Agonists |
| MeSH PA | D000700 | Analgesics |
| MeSH PA | D018712 | Analgesics, Non-Narcotic |
| MeSH PA | D002491 | Central Nervous System Agents |
| MeSH PA | D002492 | Central Nervous System Depressants |
| MeSH PA | D006993 | Hypnotics and Sedatives |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D018373 | Peripheral Nervous System Agents |
| MeSH PA | D018689 | Sensory System Agents |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Conscious sedation | indication | 314271007 | |
| Complete atrioventricular block | contraindication | 27885002 | |
| Hypovolemia | contraindication | 28560003 | |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Low blood pressure | contraindication | 45007003 | |
| Chronic heart failure | contraindication | 48447003 | |
| Bradycardia | contraindication | 48867003 | |
| Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Cardiac Decompensation | contraindication |
🐶 Veterinary Drug Use
| Species | Use | Relation |
|---|---|---|
| Cats | Preanesthesia to general anesthesia | Indication |
| Cats | Sedation and analgesia | Indication |
| Dogs | Preanesthesia to general anesthesia | Indication |
| Dogs | Sedation and analgesia | Indication |
| Dogs | Noise aversion | Indication |
🐶 Veterinary products
| Product | Applicant | Ingredients |
|---|---|---|
| Dexdomitor | Orion Corp. | 1 |
| SILEO | Orion Corp. | 1 |
| Dexmedesed | Dechra Veterinary Products LLC | 1 |
| Dexmedetomidine Hydrochloride Injection | Akorn Animal Health Inc. | 1 |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 13.36 | acidic |
| pKa2 | 6.76 | Basic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML) | PRECEDEX | HOSPIRA | N021038 | March 13, 2013 | RX | INJECTABLE | INJECTION | 8455527 | Jan. 4, 2032 | USE FOR SEDATION |
| EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML) | PRECEDEX | HOSPIRA | N021038 | March 13, 2013 | RX | INJECTABLE | INJECTION | 8455527 | Jan. 4, 2032 | USE FOR SEDATION |
| EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML) | PRECEDEX | HOSPIRA | N021038 | Nov. 14, 2014 | RX | INJECTABLE | INJECTION | 8455527 | Jan. 4, 2032 | USE FOR SEDATION |
| EQ 0.12MG BASE | IGALMI | BIOXCEL | N215390 | April 5, 2022 | RX | FILM | BUCCAL, SUBLINGUAL | 10792246 | June 26, 2039 | ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I OR II DISORDER BY SUBLINGUAL ADMINISTRATION |
| EQ 0.18MG BASE | IGALMI | BIOXCEL | N215390 | April 5, 2022 | RX | FILM | BUCCAL, SUBLINGUAL | 10792246 | June 26, 2039 | ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I OR II DISORDER BY SUBLINGUAL ADMINISTRATION |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| EQ 0.12MG BASE | IGALMI | BIOXCEL | N215390 | April 5, 2022 | RX | FILM | BUCCAL, SUBLINGUAL | April 5, 2025 | NEW PRODUCT |
| EQ 0.18MG BASE | IGALMI | BIOXCEL | N215390 | April 5, 2022 | RX | FILM | BUCCAL, SUBLINGUAL | April 5, 2025 | NEW PRODUCT |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Alpha-2B adrenergic receptor | GPCR | AGONIST | Ki | 9.70 | IUPHAR | CHEMBL | |||
| Alpha-2C adrenergic receptor | GPCR | AGONIST | Ki | 9.30 | IUPHAR | CHEMBL | |||
| Alpha-2A adrenergic receptor | GPCR | AGONIST | EC50 | 8.82 | CHEMBL | CHEMBL | |||
| Alpha-1B adrenergic receptor | GPCR | Ki | 6.50 | PDSP | |||||
| Alpha-1A adrenergic receptor | GPCR | Ki | 6.70 | PDSP | |||||
| Alpha-1D adrenergic receptor | GPCR | Ki | 10.82 | CHEMBL | |||||
| Alpha-2A adrenergic receptor | GPCR | Ki | 10.82 | CHEMBL | |||||
| Alpha-1A adrenergic receptor | GPCR | EC50 | 6.42 | CHEMBL | |||||
| Adrenergic receptor alpha-2 | GPCR | Ki | 10.82 | CHEMBL | |||||
| Adrenergic receptor alpha-1 | GPCR | Ki | 8.30 | CHEMBL | |||||
| Alpha-1B adrenergic receptor | GPCR | EC50 | 6.44 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4021214 | VUID |
| N0000148660 | NUI |
| D00514 | KEGG_DRUG |
| 145108-58-3 | SECONDARY_CAS_RN |
| 228054 | RXNORM |
| 4021214 | VANDF |
| 4021215 | VANDF |
| C0113293 | UMLSCUI |
| CHEBI:4466 | CHEBI |
| CZX | PDB_CHEM_ID |
| CHEMBL778 | ChEMBL_ID |
| DB00633 | DRUGBANK_ID |
| CHEMBL2106195 | ChEMBL_ID |
| D020927 | MESH_DESCRIPTOR_UI |
| 5311068 | PUBCHEM_CID |
| 6277 | INN_ID |
| 521 | IUPHAR_LIGAND_ID |
| 67VB76HONO | UNII |
| 227894 | MMSL |
| 29394 | MMSL |
| 8598 | MMSL |
| d04505 | MMSL |
| 008084 | NDDF |
| 008085 | NDDF |
| 116348007 | SNOMEDCT_US |
| 437750002 | SNOMEDCT_US |
| 438079000 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Dexmedetomidine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9525 | INJECTION, SOLUTION | 4 ug | INTRAVENOUS | ANDA | 30 sections |
| Dexmedetomidine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9526 | INJECTION, SOLUTION | 4 ug | INTRAVENOUS | ANDA | 30 sections |
| Dexmedetomidine HCl | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9532 | INJECTION | 100 ug | INTRAVENOUS | ANDA | 29 sections |
| DEXMEDETOMIDINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0338-9555 | INJECTION | 200 ug | INTRAVENOUS | ANDA | 30 sections |
| DEXMEDETOMIDINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0338-9557 | INJECTION | 400 ug | INTRAVENOUS | ANDA | 30 sections |
| PRECEDEX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0404-9938 | INJECTION, SOLUTION, CONCENTRATE | 100 ug | INTRAVENOUS | NDA | 17 sections |
| Precedex | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-1174 | INJECTION, SOLUTION | 4 ug | INTRAVENOUS | NDA | 35 sections |
| Precedex | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-1434 | INJECTION, SOLUTION | 4 ug | INTRAVENOUS | NDA | 34 sections |
| Precedex | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-1434 | INJECTION, SOLUTION | 4 ug | INTRAVENOUS | NDA | 34 sections |
| Precedex | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-1454 | INJECTION, SOLUTION | 4 ug | INTRAVENOUS | NDA | 35 sections |
| Precedex | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-1638 | INJECTION, SOLUTION, CONCENTRATE | 100 ug | INTRAVENOUS | NDA | 34 sections |
| Precedex | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-1638 | INJECTION, SOLUTION, CONCENTRATE | 100 ug | INTRAVENOUS | NDA | 34 sections |
| Precedex | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-1660 | INJECTION, SOLUTION | 4 ug | INTRAVENOUS | NDA | 34 sections |
| Precedex | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-1660 | INJECTION, SOLUTION | 4 ug | INTRAVENOUS | NDA | 34 sections |
| Precedex | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-3301 | INJECTION, SOLUTION | 4 ug | INTRAVENOUS | NDA | 35 sections |
| DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-3493 | INJECTION | 4 ug | INTRAVENOUS | ANDA | 29 sections |
| DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-3494 | INJECTION | 4 ug | INTRAVENOUS | ANDA | 29 sections |
| DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-3495 | INJECTION | 4 ug | INTRAVENOUS | ANDA | 29 sections |
| Dexmedetomidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16729-239 | INJECTION, SOLUTION | 100 ug | INTRAVENOUS | ANDA | 28 sections |
| DEXMEDETOMIDINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16729-432 | INJECTION, SOLUTION | 100 ug | INTRAVENOUS | ANDA | 28 sections |
| Dexmedetomidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17478-055 | INJECTION, SOLUTION, CONCENTRATE | 100 ug | INTRAVENOUS | ANDA | 32 sections |
| Dexmedetomidine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42023-146 | INJECTION, SOLUTION, CONCENTRATE | 100 ug | INTRAVENOUS | ANDA | 32 sections |
| Dexmedetomidine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42023-186 | INJECTION, SOLUTION | 4 ug | INTRAVENOUS | ANDA | 32 sections |
| Dexmedetomidine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42023-187 | INJECTION, SOLUTION | 4 ug | INTRAVENOUS | ANDA | 32 sections |
| DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43066-555 | INJECTION | 200 ug | INTRAVENOUS | ANDA | 30 sections |
| DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43066-557 | INJECTION | 400 ug | INTRAVENOUS | ANDA | 30 sections |
| DEXMEDETOMIDINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43066-561 | INJECTION | 200 ug | INTRAVENOUS | ANDA | 30 sections |
| DEXMEDETOMIDINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43066-565 | INJECTION | 400 ug | INTRAVENOUS | ANDA | 30 sections |
| DEXMEDETOMIDINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43598-975 | INJECTION, SOLUTION | 4 ug | INTRAVENOUS | ANDA | 29 sections |
| DEXMEDETOMIDINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43598-976 | INJECTION, SOLUTION | 4 ug | INTRAVENOUS | ANDA | 29 sections |